Corvus Pharmaceuticals Inc (CRVS) — Cash Flow-to-Debt Ratio
Corvus Pharmaceuticals Inc (CRVS) has a Cash Flow-to-Debt Ratio of -0.83x as of March 2026, meaning its operating cash flow of $-10.37 Million could theoretically repay -1% of its total liabilities ($12.52 Million) in one year. Explore CRVS long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Corvus Pharmaceuticals Inc Cash Flow-to-Debt Ratio (2014–2025)
Historical debt coverage capacity for Corvus Pharmaceuticals Inc across 12 annual periods. Also explore CRVS asset base for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Corvus Pharmaceuticals Inc (2014–2025)
Year-by-year debt coverage analysis for Corvus Pharmaceuticals Inc. For market capitalisation and broader financial context, see CRVS market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.31x | $-32.80 Million | $9.91 Million | ▼ -372.8% |
| 2024 | -0.70x | $-25.42 Million | $36.34 Million | ▲ +79.9% |
| 2023 | -3.48x | $-23.93 Million | $6.87 Million | ▼ -56.3% |
| 2022 | -2.23x | $-27.02 Million | $12.12 Million | ▲ +25.4% |
| 2021 | -2.99x | $-36.72 Million | $12.29 Million | ▼ -14.9% |
| 2020 | -2.60x | $-34.78 Million | $13.38 Million | ▲ +12.7% |
| 2019 | -2.98x | $-37.32 Million | $12.54 Million | ▲ +42.6% |
| 2018 | -5.19x | $-40.99 Million | $7.90 Million | ▼ -11.7% |
| 2017 | -4.65x | $-46.21 Million | $9.94 Million | ▼ -22.6% |
| 2016 | -3.79x | $-27.86 Million | $7.35 Million | ▼ -4235.3% |
| 2015 | -0.09x | $-11.33 Million | $129.56 Million | ▼ -959.3% |
| 2014 | -0.01x | $-104.73K | $12.69 Million | — |